A Robot Came to Lahore: What the First Robotic Hip Replacement at Sharif Medical City Actually Means

On the evening of 28 July 2026, between by-election results scrolling along the bottom of the screen, SUNO News gave seventy-six seconds to something quieter than politics. Sharif Medical City Hospital in Lahore had completed its first robotic-assisted hip replacement. The procedure was performed by Prof. Farooq Azam Khan and his surgical team, with technical support from Rech International, in the hospital's modular operating theatre.

That was the whole report. No patient interview, no follow-up, no cost, no outcome — the standard shape of a health-technology story anywhere in the world. What follows is the part the bulletin did not have room for: what the machine in that theatre actually does, what thirty years of evidence says it is worth, and why the same scene is being filmed this year in Nairobi, Ahmedabad, Glasgow and Chengdu.

What was actually in the room

The photographs from the case are more informative than the script. Mounted on a cart beside the table is an NDI Polaris Vega XT — an optical tracking camera that watches constellations of reflective markers pinned into the patient's pelvis and femur and reports their position, several hundred times a second, to sub-millimetre accuracy. On the screen is a three-dimensional model of the patient's pelvis, the socket speckled with registration points, and a workflow bar stepping through Calibration → Femoral Prep → Acetabular Prep → Implantation.

There is no robotic arm in the frame, and that is not a criticism — it is the design. Most systems sold under the word "robotic" in hip surgery are navigation-guided: the surgeon holds the reamer and the impactor, and the computer measures. It knows where the pelvis is, where the instrument is, and therefore exactly what angle the socket is being reamed at and exactly how much leg length and offset the reconstruction has produced. The surgeon's hands do the work; the machine removes the guesswork.

That distinction matters because the word "robot" carries an image of autonomy that no approved joint-replacement system currently has. There is a real spectrum — passive navigation, semi-active systems that constrain the tool inside a planned boundary, and robotic arms that hold a cutting guide — and hospital press releases rarely say which one they bought. If you are a patient, the useful question is not is there a robot? but what is it measuring, and what would you have done without it?

The name, honestly. The bulletin identified the platform as the "Vulcan TactileSystem (VTS)." The Urdu spelling supports several transliterations, and no commercialorthopaedic system under any of them could be verified in published sources at the timeof writing. The tracking hardware is identifiable from the photographs; the platform brandshould be treated as as-reported.

Why the hip is the joint where measurement pays

Hip replacement is one of the most successful operations in medicine — the "operation of the century," as The Lancet once called it. But its failures cluster around a small number of millimetre-and-degree problems, and they are precisely the problems a measuring system addresses.

Cup position. The socket has to sit within a fairly narrow window of tilt and rotation. Too far outside it and the ball can lever out of the socket — dislocation, the complication patients fear most and the one most likely to send them back to theatre in the first year. Judged by eye through a small incision, with the patient's pelvis free to roll on the table, even experienced surgeons miss the window more often than they would like.

Leg length and offset. A hip that comes out 12 mm long is a hip that limps, aches in the back, and generates a complaint no amount of good radiography will settle. Navigation measures the change continuously, before the final components go in, when it can still be corrected.

These are unglamorous benefits. They are also the two things patients actually notice.

What the evidence says — the encouraging half

The largest recent American analyses are genuinely supportive on short-term safety.

A nationwide propensity-matched study of nearly two million hip replacements from 2016–2022 found that robotic-assisted cases had a mean hospital stay of 1.8 days versus 2.5 days for conventional surgery, with conventional patients carrying significantly higher risks of blood transfusion (RR 1.56), deep vein thrombosis (RR 2.00) and intraoperative fracture (RR 1.39).

A separate fourteen-year cohort looking at technology-assisted hip replacement — robotics and navigation together — reported 90-day complications of 5.36% versus 6.26% (adjusted OR 0.77), with the largest single gains exactly where theory predicted them: dislocation (aOR 0.64) and periprosthetic joint infection (aOR 0.63). Wound dehiscence was slightly higher (aOR 1.15), a reminder that nothing is free.

If your worry is the first three months after a hip replacement, the technology looks like a reasonable bet.

What the evidence says — the half that gets left out of press releases

Now the counterweight, and it deserves equal weight.

The American Joint Replacement Registry, examining Medicare patients from 2017–2022, found that neither navigation nor robotics reduced the need for revision surgery at five years. The authors' phrasing is blunt: the purported benefits of using this technology to improve component survival "are not supported."

In the knee, where robotic assistance is further along, meta-analyses of randomised trials converge on the same uncomfortable finding: alignment is measurably better; function is not. Differences in knee scores reach statistical significance and stop well short of clinical significance. Patients cannot feel the improvement the X-ray can see.

And in NHS Scotland, where the ARISE programme tracked every case from 2020 to 2024, robotic procedures grew tenfold — 101 cases to 1,164 — while median operating time stayed identical at 91 minutes. The genuine gain was consistency: fewer outlier cases, tighter scheduling, a more predictable list. That is a real operational benefit. It is not the benefit the marketing describes.

So the fair summary, in 2026, is this: robotic assistance reliably improves precision, and precision has not yet been shown to translate into implants that last longer or patients who walk better a decade on. It may. The follow-up is not there yet. Anyone who tells a patient otherwise is selling something.

The same week, the same city, the same distributor

Here is the detail that makes the Lahore story more interesting than a single hospital's first case.

Seven days before the Sharif Medical City operation, Shaikh Zayed Hospital Lahore announced the first robotic total knee replacement in Punjab's public sector, led by Prof. Dr. Wasif Ali Shah — also in collaboration with Rech International, the same Karachi-based orthopaedic distributor.

Two hospitals, one city, one month, one supplier. That is not coincidence; it is a market entering a country. And it is exactly how robotic orthopaedics has entered every country that now takes it for granted: a distributor places a platform, an established surgeon becomes the proving ground, the local press reports a first, and — if the cases keep coming — a programme grows behind it.

The global picture: the same scene, filmed everywhere

United States. Technology-assisted hip replacement went from 1.2% of primary elective cases in 2010 to 12% in 2023. Robotic-assisted hips alone climbed from 1.2% in 2016 to 6.7% in 2022, and industry forecasts now project robotic assistance in a majority of hip and knee replacements by 2030. Adoption is also strikingly uneven by region, which tells you it is driven as much by hospital purchasing as by clinical need.

United Kingdom. In Scotland, despite that tenfold rise, robotic cases remained under 10% of all hip and knee replacements, and only six of twenty-three hospitals performed any at all — with two hospitals accounting for over 97% of the national total. A wealthy public health system with a national registry, and access still concentrated in two buildings.

India. MAKO, ROSA and handheld platforms are established across metro private hospitals, and in July 2025 the first fully autonomous saw-based robotic knee replacement on a live patient was performed in Ahmedabad. Indian groups are now publishing on indigenous orthopaedic robotics with explicit cost-reduction goals — the most likely route by which this technology reaches South Asian patients at scale.

China. Beijing Jishuitan Hospital completed the country's first domestically-developed robot-assisted hip replacement in 2020. Chinese systems — TiRobot, HURWA, Yuanhua's HX arm, the last explicitly designed for low-resource and remote settings — now compete on price in exactly the markets Western platforms priced themselves out of. Pakistan is one of those markets.

Africa. In December 2025, Metropolitan Hospital in Nairobi performed the first robotic-assisted knee replacements in East and Central Africa. The Kenyan coverage reads almost word for word like the Lahore coverage: a first, a milestone, a foundation for more.

The pattern repeats because the economics repeat.

The economics nobody puts in the bulletin

An orthopaedic robotic platform costs upwards of US$1.2 million in capital, plus roughly $100,000–$300,000 a year in service contracts and single-use disposables. Manufacturers increasingly offer leasing and "pay-per-click" arrangements precisely because that capital number stops most hospitals outside high-income systems — and that is how platforms are now reaching middle-income markets.

Set that against the Pakistani context. Public health spending has hovered at or below 1% of GDP for nearly three decades — 0.9% in the most recent Economic Survey, against the WHO benchmark of 5% for universal coverage. Most healthcare is paid for out of pocket at the point of service; a 2024 World Bank analysis estimated that medical bills alone would push around 11 million Pakistanis into poverty in a single year, and household survey work found roughly 13% of households facing catastrophic health expenditure — spending enough on health to cut back on food or take children out of school. A private hip replacement in Lahore currently runs somewhere around PKR 700,000 to 1.1 million, before anything is added for advanced technology.

Globally, the Lancet Commission on Global Surgery's finding still stands: five billion people lack access to safe, timely and affordable surgical care, and nine in ten people in low- and middle-income countries cannot access basic surgical services at all.

None of this is an argument against the machine. It is the context the machine arrives into, and it sets the standard the machine has to meet.

The three questions worth asking

A first case is a photograph. A programme is what happens afterwards. Three things separate the two, and they apply to Lahore exactly as they apply to Nairobi and Glasgow:

1. Volume. Precision technology rewards surgeons who use it often enough to get past its learning curve — and every published series shows a learning curve. A platform used occasionally is a platform that adds theatre time without adding accuracy. The question is not whether the first case succeeded but whether there will be a hundredth.

2. Teaching. The photographs from Sharif Medical City show eleven people around the cart, several of them clearly trainees. Navigation is an unusually good teaching tool because it makes the invisible measurable: a resident can see, numerically, what a well-positioned cup looks like and how far their own instinct was off. A robot that trains a generation of surgeons outlives the robot.

3. Access. Every country in this story has ended up with the same problem — the technology concentrating in a small number of well-funded theatres. Punjab's public sector reached its first robotic knee replacement one week before this hip. Whether that becomes a trend or a one-off photograph is the single most consequential question in this whole story, and it will not be answered by surgeons.

What this means if you are the patient

If you are considering a hip replacement in Pakistan and reading about robots, a few honest points:

• The surgeon matters more than the platform. Every serious analysis of joint replacement outcomes finds surgeon and hospital volume to be stronger predictors than the technology in the room. Ask how many hip replacements your surgeon performs a year, and ask that first.
• Ask what the technology is being used to measure — cup position, leg length, offset — and what it would change about your particular hip. If the answer is generic, the technology is decoration.
• Do not pay a large premium for a promise the evidence has not yet delivered. Short-term safety signals are encouraging; long-term superiority is unproven. A well-executed conventional hip replacement by an experienced surgeon remains an excellent operation.
• Ask about the whole pathway. Anaesthesia, infection control, physiotherapy on day one, and follow-up determine your recovery far more than the guidance system did.

The machine that arrived in Lahore last week is a good machine, doing a genuinely useful job. It measures what surgeons have historically had to estimate. That is worth reporting — and it is worth reporting accurately, because the gap between what this technology does and what people assume it does is where disappointment lives.

Seventy-six seconds on a by-election night was, in the end, about right for the news. The rest of it is the work.

Sources: SUNO News bulletin, 28 July 2026; ProPakistani and Dunya News reporting on Shaikh Zayed Hospital, 21–23 July 2026; National Inpatient Sample analysis of robotic-assisted THA 2016–2022; fourteen-year technology-assisted THA cohort, 2010–2023; American Joint Replacement Registry five-year survivorship analysis, 2017–2022; NHS Scotland ARISE programme data, 2020–2024; Lancet Commission on Global Surgery; Pakistan Economic Survey 2024–25; World Bank health financing data.

This article is general information, not medical advice.